A Study of RO5045337 in Patients With Solid Tumors

An Open-Label, Randomized 3-Way Crossover, Study to Examine the Food-Effect on Pharmacokinetics of the Current Formulation and Relative Bioavailability of Two New Formulations for RO5045337 in Patients With Solid Tumors Including Lymphoma

This open-label, randomized, cross-over study will evaluate the effect of food on the pharmacokinetics of single oral doses of RO5045337 in patients with solid tumors. The anticipated time on study treatment is 3 weeks.

Inclusion Criteria:

• Adult patients, >/=18 years of age
• Histologically confirmed solid tumor
• Life expectancy of >/=12 weeks
• ECOG performance status of 0 or 1
• Adequate bone marrow, renal and hepatic function

Exclusion Criteria:

• Patients receiving any other investigational agent or therapy administered with the intention to treat their malignancy within 28 days prior to study start
• Patients with pre-existing gastro-intestinal disorder
• Patients with uncontrolled intercurrent illness